Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 11/2020 | Adagio Medical | Series E | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 9/2014 | Affimed | Debt Financing | 14M |
| 2/2022 | Omada Health | Series E | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 9/2020 | Willow | Series C | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 4/2021 | Forge Biologics | Series B | 120M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 10/2021 | Honor | Debt Financing | 300M |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 7/2018 | Alector | Series E | 133M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 1/2022 | AvengeBio | Series A | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 5/2017 | Xontogeny | Series A | 15M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 5/2019 | ArcherDX | Series B | 60M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 9/2018 | Vapotherm | Series D | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 1/2021 | Earli | Series A | 40M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 10/2021 | Twin Health | Series C | 155M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 11/2017 | Counsyl | Equity | 80M |
| 5/2017 | Outset Medical | Series C | 0 |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 3/2019 | Saama | Venture Round | 40M |
| 5/2021 | Cue | Venture Round | 235M |
| 6/2016 | VitalConnect | Series B | 18M |
| 10/2020 | LianBio | Series A | 0 |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 4/2019 | Kindbody | Series A | 15M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 8/2020 | Freenome | Series C | 270M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 8/2018 | ReViral | Series B | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 11/2021 | Sermonix | Series A | 40M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 1/2021 | Affinivax | Series C | 226M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 7/2019 | Kronos Bio | Series A | 105M |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 12/2020 | Neuron23 | Series B | 80M |
| 7/2020 | Kindbody | Series B | 0 |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 5/2020 | Atea | Series D | 215M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 2/2022 | Synthego | Series E | 0 |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 3/2022 | DNAnexus | Series H | 200M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 10/2014 | Invitae | Series F | 0 |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 7/2019 | Freenome | Series B | 160M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 4/2014 | Otonomy | Series D | 49M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 3/2022 | Neuron23 | Series C | 0 |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2020 | Metabolon | Venture Round | 72M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 1/2021 | IsoPlexis | Series D | 85M |
| 4/2021 | Renovia | Series C | 0 |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 3/2021 | Absci | Venture Round | 0 |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 5/2017 | Synlogic | Series C | 42M |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Genome Medical | Series B | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 8/2020 | ReViral | Series C | 0 |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 4/2022 | Surf Bio | Seed | 16M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
